Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.57 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.50 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.50 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401436 | 1.00 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL29676554 | 1.00 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27821605 | 0.98 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4779807 | 0.96 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL20744151 | 0.90 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2908394 | 0.88 | CHRM1 (0.51) | L3MBTL3L3MBTL1 | |
| SCHEMBL20744086 | 0.88 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1MEN1KMT2A | |
| SCHEMBL20744085 | 0.88 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1MEN1KMT2A | |
| SCHEMBL2862492 | 0.87 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL18125956 | 0.86 | CHRM1 (0.50) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370405-B2 | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2019-08-06 | — | — | US | disclosed |
| US-20180237472-A1 | C-3 NOVEL TRITERPENONE WITH C-28 AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2018-08-23 | — | — | US | disclosed |
| EP-2250167-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | Chlorion Pharma, Inc. (CA) | 2010-11-17 | — | — | EP | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | L3MBTL3 2314/4885L3MBTL1 3557/4885MBTD1 2165/4885 |
| US-20180237472-A1 | C-3 NOVEL TRITERPENONE WITH C-28 AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, GTF3C3 | L3MBTL3 1400/4885L3MBTL1 2147/4885MBTD1 2151/4885 |
| US-10370405-B2 | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors | ERG28, CCR3, GTF3C3 | L3MBTL3 1400/4885L3MBTL1 2147/4885MBTD1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.